Conference Coverage

East Village, San Diego. Photo by Derek Story on Unsplash

Conference Update – 10th Annual World ADC San Diego 2019

With the recent accelerated approval from the FDA for Genentech’s Polivy for patients with relapsed or refractory diffuse large...
Featured Image: Close-up cityscape of Lugano city waterfront along Lugano Lake. Facades of historic houses in front of alp mountains. Courtesy: © 2017. Fotolia. Used with permission.

15th ICML: Camidanlumab Tesirine Shows High Overall Response Rate in R/R Classical Hodgkin Lymphoma

During the International Conference on Malignant Lymphoma (ICML), one of the must-attend events for the scientific community involved in...

15th ICML: Loncastuximab Tesirine Shows Significant Activity in R/R Diffuse Large B-cell Lymphoma

Loncastuximab tesirine (ADCT‐402), an anti‐CD19 antibody‐drug conjugate (ADC) conjugated via a protease cleavable linker to SG3199, a highly cytotoxic...

15th ICML ADC Presentation Overview

The International Conference on Malignant Lymphoma (ICML), which will be held June 18-22, 2019 in the Palazzo dei Congressi,...
Featured Image: View of Lugano old town with mountains in the background, Switzerland. Courtesy: © 2017. Fotolia. Used with permission.

Pyrrolobenzodiazepine-based ADCs Demonstrate Potential in R/R Lymphomas

The International Conference on Malignant Lymphoma (ICML) has, since its first edition in 1981, become one of the must-attend...

World ADC Highlights

Watch the 2018 World ADC San Diego video to get a flavor of what the event is all about....

EHA 2019: Belantamab Mafodotin in Patients with R/R Multple Myeloma

New, updated, data on belantamab mafodotin, also known as GSK2857916, an investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC),...
General views from the 2019 Annual Meeting of the American Society (ASCO), held May 31 - June 4, 2019. Courtesy © ASCO/Phil McCarten 2019.

RC48-ADC Demonstrates Clinically Meaningful Results in HER2+ Metastatic and Unresectable Urothelial Cancer

Clinically meaningful topline results for a Phase II clinical trial of RC48-ADC were presented during the annual meeting of...
General Views of the 55th Annual Meeting meeting of the American Society of Clinical Oncology. Photo Courtesy: © ASCO/Nick Agro 2019.

Preliminary Phase I Data for U3-1402 Shows Manageable Safety and Reduction in Tumor Size...

Preliminary results from the dose escalation part of the phase I study with U3-1402, an investigational and potential first-in-class...
Exhibition booth Seattle Genetics - ASCO 2019 | Courtsey: Emila Duaerte / Sunvalley Communication

Phase III Clinical Trials of Brentuximab Vedotin Continue to Demonstrate Superior Clinical Activity

Additional, updated, analyses of results from ECHELON-1 and ECHELON-2, the frontline phase III trials of brentuximab vedotin (Adcetris®; Seattle...